Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

Enfortumab vedotin

Enfortumab vedotin
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Padcev POWDER FOR INJECTION, INTRAVENOUS 20 mg. 30 mg        
Comments:

Restricted to oncology in the outpatient setting. Insurance certification or PAP eligibility review required with each case before use. May be administered as "patient own medication" through PAP.

Miscellaneous Programs

Anti-Neoplastic Formulary

 

Reviewed: July 2020

High Value Care Committee: May 2021 - Approved

Last updated: Mar. 29, 2026
Rhazdrugs Enfortumab vedotin






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved